Universal Ibogaine Inc · TSXV:IBO
Universal Ibogaine — Investor Presentation (March 2025)
25 slides from Universal Ibogaine's investor presentation, Mar 25, 2025
Slide 1: Transforming Addiction Treatment with Ibogaine
TSXV: IBO OTC PINK: IBOGF FSE: JC4 TRANSFORMING ADDICTION TREATMENT WITH IBOGAINE MARCH 25, 2025
Slide 2: Strategic Pillars: Development, Licensing, Delivery
UNIVERSAL IBOGAINE STRATEGIC PILLARS DEVELOPMENT LICENSING DELIVERY STRATEGIC PILLARS 2
Slide 3: Disclaimer and Use of Forward-Looking Statements
DISCLAIMER AND USE OF FORWARD-LOOKING STATEMENTS This presentation is provided for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities. It has been provided solely to
Slide 4: Contents
CONTENTS 1 OUR PURPOSE 2 THE ADDICTION CRISIS 3 IBOGAINE IS A SOLUTION 4 WHAT IS IBOGAINE & HOW DOES IT WORK 5 IBOGAINE IN THE MAINSTREAM MEDIA 6 UNIVERSAL IBOGAINE’S MISSION & HISTORY 7 STRATEGIC PILLARS & INVESTMENT HIGHLIGHTS 8 CLINICAL TRIAL ROADMAP 9 POTENTIAL FUTURE REVENUE DRIVERS 10 MARKET P
Slide 5: Our Purpose
OUR PURPOSE Universal Ibogaine plans to deliver Ibogaine as a viable solution to the Addiction and Overdose Crisis, through a proven treatment protocol and global licensing model. OUR MISSION 5
Slide 6: The Addiction Crisis
THE ADDICTION CRISIS Over 100,000 Overdose Deaths in the USA over the last 12 months with opioids accounting for 75%. (1) Drug Overdose is the leading cause of accidental death in the USA. (2) THE ADDICTION CRISIS 6
Slide 7: The Addiction Crisis: Key Statistics
THE ADDICTION CRISIS 1 in 5 35 Million 90% Canadian adults will People require professional Relapse rate associated with experience addiction (3) treatment for addiction current treatment modalities (5) globally (4) 93% $1.3 Trillion 300% Increase in overdose deaths Annual economic toll of Opioid An
Slide 8: Ibogaine Is a Solution
IBOGAINE IS A SOLUTION Empirical evidence indicates: Painless Drug Detoxification in 18 to 24 hours Resets the brain to a Pre-addicted state Removes Drug Cravings for 2 to 4 months IBOGAINE IS THE SOLUTION 8
Slide 9: What Is Ibogaine?
WHAT IS IBOGAINE? Ibogaine refers to a naturally occurring psychoactive indole alkaloid. It is derived from the roots of the African rainforest shrub Tabernathe iboga and part of the Apocynaceae family. Traditionally used by the Bwiti people of Western Africa, ibogaine helped individuals curb fatigu
Slide 10: How Does Ibogaine Work?
HOW DOES IBOGAINE WORK? Ibogaine is a fast-acting, plant derived substance that interrupts drug addiction symptoms. Ibogaine helps a drug dependent person safely and effectively return to their pre-addicted state. Ibogaine connects with multiple neurotransmitter systems including the sigma-2 recepto
Slide 11: Nothing Does What Ibogaine Can Do
NOTHING DOES WHAT IBOGAINE CAN DO KETAMINE PSILOCYBIN MDMA LSD IBOGAINE (48 hours) (2 weeks) (2 weeks) (3 weeks) (4 weeks) Critical Open State (Mice) Psychedelics Reopen the social Reward Learning Critical period: Duration of the open state 1 2 3 4 Time (weeks post injection) Nardou et al, Nature 20
Slide 12: Ibogaine in the Mainstream Media
IBOGAINE IN THE MAINSTREAM MEDIA Harvard Medical The Washington Post The New York Times TIME Discover Magazine Forbes Rolling Stone School Magazine Inside Ibogaine, One Ibogaine:The U.S. Government Will How a Psychedelic 12- Back to the future: Who Will Benefit From The promises and of the Most Prom
Slide 13: Universal Ibogaine's Mission
UNIVERSAL IBOGAINE’S MISSION Universal Ibogaine is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements.
Slide 14: History of Universal Ibogaine
HISTORY OF UNIVERSAL IBOGAINE Universal Ibogaine was born in 2018 when Canadian financier Shayne Nyquvest met Dr. Alberto Sola, the world's most experienced ibogaine treatment provider. Dr. Sola's ibogaine treatment protocol has disrupted addiction by safely administering over 3,700 treatments to pa
Slide 15: Planned Long Term Strategic Pillars
PLANNED LONG TERM STRATEGIC PILLARS IBOGAINE DEVELOPMENT Medicalize ibogaine hydrochloride molecule through clinical trial in Canada for the treatment of opioid use disorder. LICENSING License our ibogaine treatment protocol to Detox Centers and Addiction Treatment Facilities around the world. DELIV
Slide 16: Strategic Pillar Highlights
STRATEGIC PILLAR HIGHLIGHTS Driving Value with Integrity for our Shareholders Potential for exclusive IBOGAINE Ibogaine Clinical Trial in Canada Drug Identification Number ibogaine provider for medical DEVELOPMENT Medicalization use in North America 16,000+ Addiction Treatment Global addiction treat
Slide 17: Clinical Trial Roadmap
CLINICAL TRIAL ROADMAP DRUG (IBOGAINE) DEVELOPMENT PROGRAM: PROJECTED ROADMAP MILESTONES Secure GMP Semi-Synthetic Ibogaine Hydrochloride 2025 Pre Clinical Trial Application (CTA) Meetings in progress Pre-CTA Meetings CTA Submission NOL 2026 Clinical Trial Application No Objection Letter (NOL) Phase
Slide 18: Potential Future Revenue Drivers
POTENTIAL FUTURE REVENUE DRIVERS DRUG MANUFACTURING & DISTRIBUTION Planned clinical trial in Canada to demonstrate safety and efficacy of our ibogaine based treatment protocol may yield exclusive drug and treatment protocol distribution rights. LICENSING TREATMENT PROTOCOLS Scalable monthly recurrin
Slide 19: Market Potential
MARKET POTENTIAL 1,500+ clinics CANADA UNITED STATES 14,500+ clinics MEXICO MARKET POTENTIAL 19
Slide 20: Operating Clinic – Kelburn Recovery Center
OPERATING CLINIC – KELBURN RECOVERY CENTER State of the Art ibogaine aftercare program development site & possible clinical trial location Fully operational revenue generating addiction treatment center located near Winnipeg , Manitoba, Canada, acquired in 2021. OPERATING CLINIC 20
Slide 21: Capital Structure
CAPITAL STRUCTURE TOTALS AS AT MARCH 25, 2025 EXERCISE PRICE TERM/EXPIRY TOTAL # (MILLIONS) NOTE 1) 308.6 SHARES ISSUED AND OUTSTANDING ADDITIONAL SHARES RESERVED FOR ISSUANCE OPTIONS (DIRECTORS, OFFICERS AND KEY PEOPLE) Average $0.23 5 to 10 YEARS 4.3 SHARE PURCHASE WARRANTS (5 YEAR TERM) NOTE 2) A
Slide 22: ESG Responsibility
ESG RESPONSIBILITY ENVIRONMENT - UI will pursue a semi-synthetic drug supply using plant derived source while preserving the iboga root for indigenous cultural use SOCIAL - Commitment to both Purpose and Profit - Universal Ibogaine is a Pure Play Social Impact Organization GOVERNANCE - Diverse and I
Slide 23: Board & Management
BOARD & MANAGEMENT NICK KAROS DR. DEAN KOUMONTZIS JAMES DUNCAN Chief Executive Officer Director Director Director KEN CRANWILL GREG LEAVENS Director Chief Financial Officer MANAGEMENT TEAM 23
Slide 24: Thank You
TSXV: IBO OTCPINK: IBOGF FSE: JC4 THANK YOU NICK KAROS CEO NICK.KAROS@UNIVERSALIBOGAINE.COM
Slide 25: Sources
Sources 1. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm 2. https://pubmed.ncbi.nlm.nih.gov/29262202/#:~:text=Drug%20overdose%20is%20the%20leading%20cause%20of%20accidental,and%20about%2091%20opioid%20overdose%20deaths%20every%20day 3. https://www.camh.ca/en/driving-change
Universal Ibogaine — Investor Presentation (March 2025) on 6ix